Omalizumab as a last resort therapy for intractable, severe chronic allergic rhinosinusitis
- 22 Downloads
Allergic rhinitis (AR) is a highly prevalent condition affecting 10 to 40% of the general population. Symptomatic AR has a negative impact on daily activities and may result in absenteeism or reduced productivity and performance at work. Although therapy for AR is well codified, there still remains a considerable proportion of patients who fail to respond to standard therapy and remain a challenge in every day clinical practice.
Omalizumab, a humanized anti-IgE monoclonal antibody, is currently licensed for moderate to severe allergic asthma and chronic urticaria. Because of its mechanism(s) of action, omalizumab may theoretically be useful in several IgE-mediated diseases in case of poor control with standard therapy. Indeed, a number of case reports or small case series can be retrieved from the medical literature with regard to further potential uses of omalizumab in diseases other than allergic asthma and chronic urticaria where IgE may be supposed to play a pathogenic...
KeywordsAllergic rhinitis Sinusitis Omalizumab Off-label Treatment
Conflict of interest
C. Romano, G. Pace, A. Sellitto and A. Reginelli declare that they have no competing interests.
- 6.Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2:332–40:e1.Google Scholar